ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
23 announcements with these filters
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus Life Sciences Limited will acquire a 76% stake in IQGEN-X Pharma Private Limited for approximately ₹9.12 Crore. This strategic acquisition enhances the company's CDMO solution offerings.
Alivus Life Sciences submitted its Business Responsibility & Sustainability Report for FY 2025-26, detailing operational metrics, employee statistics, and sustainability performance.
Alivus Life Sciences Limited has filed its Integrated Annual Report for FY 2025-26 in compliance with Regulation 34(1) of SEBI Listing Regulations.
Alivus Life Sciences will hold its 15th AGM on September 8, 2026. The company fixed September 1, 2026, as the record date for a Rs. 5.00 dividend.
Alivus reported strong Q1 FY27 results with 6.4% revenue growth, masking a massive 52.6% decline in its legacy GPL business through high-margin non-GPL growth and operational efficiencies.
Alivus Life Sciences allotted 32,000 equity shares under its Employee Stock Option Scheme, 2021. This increases the company's total paid-up share capital.
Alivus Life Sciences delivered strong Q1FY27 performance with revenue at ₹6,404 Mn and EBITDA margins expanding to 36.6%. The company is pivoting towards Non-GPL segments and CDMO growth.
Alivus Life Sciences reported Q1 FY27 financial highlights with revenue growing 6.4% YoY to Rs. 6,404 million and PAT rising 31.8% YoY.
Alivus Life Sciences Ltd reported revenue from operations of ₹640.4 Cr (+6.4% YoY) and net profit of ₹160.1 Cr (+31.8% YoY) for Q1 FY27.
Alivus Life Sciences scheduled a board meeting for July 30, 2026. The meeting aims to approve unaudited financial results for the quarter ended June 30, 2026.
Alivus (ex-Glenmark Life Sciences) reported strong Q4FY26 results with record 33.6% EBITDA margins, driven by non-GPL growth (71% of business) and CDMO recovery.
Alivus (formerly Glenmark Life Sciences) delivered record FY26 EBITDA margins of 33.6%, shifting successfully from GPL dependency to a more profitable non-GPL segment despite a major plant fire and global headwinds.
Alivus reported Q4FY26 revenue of ₹6,891 Mn (6.1% YoY) and PAT of ₹1,627 Mn (14.7% YoY). Strategy shifts from Glenmark-heavy mix to non-GPL (71% of revenue) under Nirma ownership.
Alivus Life Sciences reported FY26 revenue growth of 6.9% YoY and EBITDA margins of 33.6%. The company also announced a new R&D centre in Taloja.
Alivus Life Sciences allotted 3,100 equity shares following employee stock option exercises. This marginal expansion of paid-up capital reflects the ongoing implementation of its ESOP scheme.
Alivus Life Sciences Ltd reported revenue from operations of ₹689.1 Cr (+6.1% YoY) and net profit of ₹162.7 Cr (+14.7% YoY) for Q4 FY26.
Alivus Life Sciences approved FY2025-26 audited results and recommended a ₹5 per share final dividend. The company reported annual revenue from operations of ₹2,551.83 Crore.
Alivus Life Sciences scheduled a board meeting for May 14, 2026. Directors will approve annual audited results and consider a dividend recommendation for shareholders.
Alivus Life Sciences Limited filed its Annual Secretarial Compliance Report for FY2025-26. The report confirms full regulatory compliance with no adverse observations from the practicing company secretary.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) confirmed it is not identified as a Large Corporate for the financial year. The company reported zero outstanding borrowings as of March 31, 2026, and is therefore not required to submit incremental debt disclosures under SEBI's framework.
Alivus Life Sciences Ltd reported net profit of ₹150 Cr (+9.5% YoY) for Q3 FY26.